Serum β-glucuronidase as a potential colon cancer marker: a preliminary study | Zendy

Napoleon Waszkiewicz | Zendy; Sławomir Dariusz Szajda | Zendy; Emilia Duchnowska | Zendy; Beata ZalewskaSzajda | Zendy; Robert Gałązkowski | Zendy; Anna Sawko | Zendy; Halim Nammous | Zendy; Vyacheslav Buko | Zendy; Agata Szulc | Zendy; Krzysztof Zwierz | Zendy; Jerzy Robert Ładny | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum β-glucuronidase as a potential colon cancer marker: a preliminary study

Author(s) -

Napoleon Waszkiewicz,

Sławomir Dariusz Szajda,

Emilia Duchnowska,

Beata ZalewskaSzajda,

Robert Gałązkowski,

Anna Sawko,

Halim Nammous,

Vyacheslav Buko,

Agata Szulc,

Krzysztof Zwierz,

Jerzy Robert Ładny

Publication year - 2015

Publication title -

postępy higieny i medycyny doświadczalnej

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.275

H-Index - 34

eISSN - 1732-2693

pISSN - 0032-5449

DOI - 10.5604/17322693.1148704

Subject(s) - colorectal cancer , glucuronidase , medicine , adenocarcinoma , cancer , gastroenterology , colorectal adenocarcinoma , oncology , enzyme , biology , biochemistry

Colorectal cancer is characterized by high morbidity and mortality in developed countries. The lack of low-cost, easy-to-use screening diagnostic methods is one of the causes of late diagnosis of colorectal cancer. Beta-glucuronidase (GLU) is a lysosomal exoglycosidase involved in degradation of glycosaminoglycans of the cell membranes and extracellular matrix of normal and cancerous colon tissues. The aim of our research was to evaluate the activity of GLU in the serum of colorectal cancer and estimate its potential value in the diagnosis of colorectal cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research